Search Cancer Clinical Trials

Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
100 results
  • Lymphoma

25-006          Phase II

A Phase 2 Study of Outpatient Epcoritamab as Second Line Therapy in Non-Transplant Eligible Relapsed/Refractory Large B-cell Lymphoma

  • Breast Cancer

19-578          Phase II

A Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized Breast Cancer (NeoSTAR)

  • Lymphoma

25-007          Phase II

A Phase 2 Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  • Pancreatic Cancer

22-216          Phase II

A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or von Hippel-Lindau (VHL) Disease-Associated Tumors

  • Pediatric Cancers

22-002          Phase II

A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

  • Cellular Therapy

24-317          Phase II

A Phase 2 trial of emapalumab for the prevention of CAR-T cell associated toxicities

  • Brain Tumors

23-225          Phase II

A Phase 2, multicenter, open label, two parts clinical study to evaluate the efficacy and safety of safusidenib erbumine in patients with isocitrate dehydrogenase 1 (IDH1) mutant glioma

  • Cellular Therapy, Multiple Myeloma

24-044          Phase II

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

  • Lymphoma, Cellular Therapy

25-059          Phase II

A Phase 2, open-label, multicenter study of MB-105 in patients with CD5 positive (CD5+) relapsed / refractory T-cell lymphoma (r/r TCL)

  • Cellular Therapy, Lymphoma

20-011          Phase II

A Phase 2, Open-Label, Single-Arm, Multicohort, Multicenter Trial To Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)

Showing 1 - 10 of 100 results